{"id":406,"date":"2015-09-09T15:59:11","date_gmt":"2015-09-09T15:59:11","guid":{"rendered":"http:\/\/uchealth.com\/cardiovascular-insights\/?p=406"},"modified":"2016-09-19T15:20:53","modified_gmt":"2016-09-19T15:20:53","slug":"are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins","status":"publish","type":"post","link":"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/","title":{"rendered":"Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins?"},"content":{"rendered":"<p><a href=\"\/wp-content\/uploads\/sites\/37\/2015\/09\/Steen-PSCK9-Video-Screenshot.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-thumbnail wp-image-418\" src=\"\/wp-content\/uploads\/sites\/37\/2015\/09\/Steen-PSCK9-Video-Screenshot-150x150.jpg\" alt=\"Dylan Steen, MD\" width=\"150\" height=\"150\" srcset=\"\/wp-content\/uploads\/sites\/37\/2015\/09\/Steen-PSCK9-Video-Screenshot-150x150.jpg 150w, \/wp-content\/uploads\/sites\/37\/2015\/09\/Steen-PSCK9-Video-Screenshot-96x96.jpg 96w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/a><a href=\"http:\/\/www.medpagetoday.com\/PCSK9SpecialReport\/Cardiology\/Dyslipidemia-Videos\/1283\" target=\"_blank\">PCSK9 inhibitors<\/a> are a new class of drugs, not yet FDA-approved, that have been shown to dramatically lower LDL cholesterol levels. Three clinicians discuss their potential. Video includes comments by <a href=\"https:\/\/www.uchealth.com\/physician\/dylan-steen\/\" target=\"_blank\">Dylan Steen<\/a>, MD, Department of Internal Medicine, Division of Cardiovascular Health and Disease, and UC Health cardiologist. <a href=\"http:\/\/www.medpagetoday.com\/PCSK9SpecialReport\/Cardiology\/Dyslipidemia-Videos\/1283\" target=\"_blank\">View the video<\/a>.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>PCSK9 inhibitors are a new class of drugs, not yet FDA-approved, that have been shown to dramatically lower LDL cholesterol levels. Three clinicians discuss their potential. Video includes comments by Dylan Steen, MD, Department of Internal Medicine, Division of Cardiovascular Health and Disease, and UC Health cardiologist. View the video. &nbsp;<\/p>\n","protected":false},"author":85,"featured_media":418,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1,4],"tags":[91,90,88,87,89],"class_list":["post-406","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-videos","tag-dylan-steen","tag-high-cardiovascular-risk","tag-hyperlipidemia","tag-pcsk9-inhibitors","tag-statins"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.10 - aioseo.com -->\n\t<meta name=\"description\" content=\"PCSK9 inhibitors are a new class of drugs, not yet FDA-approved, that have been shown to dramatically lower LDL cholesterol levels. Three clinicians discuss their potential. Video includes comments by Dylan Steen, MD, Department of Internal Medicine, Division of Cardiovascular Health and Disease, and UC Health cardiologist. View the video.\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"jimnilson\"\/>\n\t<meta name=\"keywords\" content=\"dylan steen,high cardiovascular risk,hyperlipidemia,pcsk9 inhibitors,statins\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.10\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Cardiovascular Insights | Responsive Medical Health WordPress Theme\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins? | Cardiovascular Insights\" \/>\n\t\t<meta property=\"og:description\" content=\"PCSK9 inhibitors are a new class of drugs, not yet FDA-approved, that have been shown to dramatically lower LDL cholesterol levels. Three clinicians discuss their potential. Video includes comments by Dylan Steen, MD, Department of Internal Medicine, Division of Cardiovascular Health and Disease, and UC Health cardiologist. View the video.\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2015-09-09T15:59:11+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2016-09-19T15:20:53+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins? | Cardiovascular Insights\" \/>\n\t\t<meta name=\"twitter:description\" content=\"PCSK9 inhibitors are a new class of drugs, not yet FDA-approved, that have been shown to dramatically lower LDL cholesterol levels. Three clinicians discuss their potential. Video includes comments by Dylan Steen, MD, Department of Internal Medicine, Division of Cardiovascular Health and Disease, and UC Health cardiologist. View the video.\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\\\/#article\",\"name\":\"Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins? | Cardiovascular Insights\",\"headline\":\"Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins?\",\"author\":{\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/author\\\/jimnilson\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"\\\/wp-content\\\/uploads\\\/sites\\\/37\\\/2015\\\/09\\\/Steen-PSCK9-Video-Screenshot.jpg\",\"width\":656,\"height\":471,\"caption\":\"Dylan Steen, MD\"},\"datePublished\":\"2015-09-09T15:59:11+00:00\",\"dateModified\":\"2016-09-19T15:20:53+00:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\\\/#webpage\"},\"articleSection\":\"Articles, Videos, dylan steen, High Cardiovascular Risk, Hyperlipidemia, PCSK9 Inhibitors, Statins\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/category\\\/articles\\\/#listItem\",\"name\":\"Articles\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/category\\\/articles\\\/#listItem\",\"position\":2,\"name\":\"Articles\",\"item\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/category\\\/articles\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\\\/#listItem\",\"name\":\"Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins?\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\\\/#listItem\",\"position\":3,\"name\":\"Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins?\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/category\\\/articles\\\/#listItem\",\"name\":\"Articles\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/#organization\",\"name\":\"Cardiovascular Insights\",\"description\":\"Responsive Medical Health WordPress Theme\",\"url\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/author\\\/jimnilson\\\/#author\",\"url\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/author\\\/jimnilson\\\/\",\"name\":\"jimnilson\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eab66967f9a597193795050a4bf175fb1122a04a50d58564f2501d9064a00eaa?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"jimnilson\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\\\/#webpage\",\"url\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\\\/\",\"name\":\"Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins? | Cardiovascular Insights\",\"description\":\"PCSK9 inhibitors are a new class of drugs, not yet FDA-approved, that have been shown to dramatically lower LDL cholesterol levels. Three clinicians discuss their potential. Video includes comments by Dylan Steen, MD, Department of Internal Medicine, Division of Cardiovascular Health and Disease, and UC Health cardiologist. View the video.\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/author\\\/jimnilson\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/author\\\/jimnilson\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"\\\/wp-content\\\/uploads\\\/sites\\\/37\\\/2015\\\/09\\\/Steen-PSCK9-Video-Screenshot.jpg\",\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\\\/#mainImage\",\"width\":656,\"height\":471,\"caption\":\"Dylan Steen, MD\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\\\/#mainImage\"},\"datePublished\":\"2015-09-09T15:59:11+00:00\",\"dateModified\":\"2016-09-19T15:20:53+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/#website\",\"url\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/\",\"name\":\"Cardiovascular Insights\",\"description\":\"Responsive Medical Health WordPress Theme\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.uchealth.com\\\/cardiovascular-insights\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins? | Cardiovascular Insights","description":"PCSK9 inhibitors are a new class of drugs, not yet FDA-approved, that have been shown to dramatically lower LDL cholesterol levels. Three clinicians discuss their potential. Video includes comments by Dylan Steen, MD, Department of Internal Medicine, Division of Cardiovascular Health and Disease, and UC Health cardiologist. View the video.","canonical_url":"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/","robots":"max-image-preview:large","keywords":"dylan steen,high cardiovascular risk,hyperlipidemia,pcsk9 inhibitors,statins","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/#article","name":"Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins? | Cardiovascular Insights","headline":"Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins?","author":{"@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/author\/jimnilson\/#author"},"publisher":{"@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/#organization"},"image":{"@type":"ImageObject","url":"\/wp-content\/uploads\/sites\/37\/2015\/09\/Steen-PSCK9-Video-Screenshot.jpg","width":656,"height":471,"caption":"Dylan Steen, MD"},"datePublished":"2015-09-09T15:59:11+00:00","dateModified":"2016-09-19T15:20:53+00:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/#webpage"},"isPartOf":{"@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/#webpage"},"articleSection":"Articles, Videos, dylan steen, High Cardiovascular Risk, Hyperlipidemia, PCSK9 Inhibitors, Statins"},{"@type":"BreadcrumbList","@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.uchealth.com\/cardiovascular-insights#listItem","position":1,"name":"Home","item":"https:\/\/www.uchealth.com\/cardiovascular-insights","nextItem":{"@type":"ListItem","@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/category\/articles\/#listItem","name":"Articles"}},{"@type":"ListItem","@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/category\/articles\/#listItem","position":2,"name":"Articles","item":"https:\/\/www.uchealth.com\/cardiovascular-insights\/category\/articles\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/#listItem","name":"Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins?"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.uchealth.com\/cardiovascular-insights#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/#listItem","position":3,"name":"Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins?","previousItem":{"@type":"ListItem","@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/category\/articles\/#listItem","name":"Articles"}}]},{"@type":"Organization","@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/#organization","name":"Cardiovascular Insights","description":"Responsive Medical Health WordPress Theme","url":"https:\/\/www.uchealth.com\/cardiovascular-insights\/"},{"@type":"Person","@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/author\/jimnilson\/#author","url":"https:\/\/www.uchealth.com\/cardiovascular-insights\/author\/jimnilson\/","name":"jimnilson","image":{"@type":"ImageObject","@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/eab66967f9a597193795050a4bf175fb1122a04a50d58564f2501d9064a00eaa?s=96&d=mm&r=g","width":96,"height":96,"caption":"jimnilson"}},{"@type":"WebPage","@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/#webpage","url":"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/","name":"Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins? | Cardiovascular Insights","description":"PCSK9 inhibitors are a new class of drugs, not yet FDA-approved, that have been shown to dramatically lower LDL cholesterol levels. Three clinicians discuss their potential. Video includes comments by Dylan Steen, MD, Department of Internal Medicine, Division of Cardiovascular Health and Disease, and UC Health cardiologist. View the video.","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/#website"},"breadcrumb":{"@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/#breadcrumblist"},"author":{"@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/author\/jimnilson\/#author"},"creator":{"@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/author\/jimnilson\/#author"},"image":{"@type":"ImageObject","url":"\/wp-content\/uploads\/sites\/37\/2015\/09\/Steen-PSCK9-Video-Screenshot.jpg","@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/#mainImage","width":656,"height":471,"caption":"Dylan Steen, MD"},"primaryImageOfPage":{"@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/#mainImage"},"datePublished":"2015-09-09T15:59:11+00:00","dateModified":"2016-09-19T15:20:53+00:00"},{"@type":"WebSite","@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/#website","url":"https:\/\/www.uchealth.com\/cardiovascular-insights\/","name":"Cardiovascular Insights","description":"Responsive Medical Health WordPress Theme","inLanguage":"en-US","publisher":{"@id":"https:\/\/www.uchealth.com\/cardiovascular-insights\/#organization"}}]},"og:locale":"en_US","og:site_name":"Cardiovascular Insights | Responsive Medical Health WordPress Theme","og:type":"article","og:title":"Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins? | Cardiovascular Insights","og:description":"PCSK9 inhibitors are a new class of drugs, not yet FDA-approved, that have been shown to dramatically lower LDL cholesterol levels. Three clinicians discuss their potential. Video includes comments by Dylan Steen, MD, Department of Internal Medicine, Division of Cardiovascular Health and Disease, and UC Health cardiologist. View the video.","og:url":"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/","article:published_time":"2015-09-09T15:59:11+00:00","article:modified_time":"2016-09-19T15:20:53+00:00","twitter:card":"summary","twitter:title":"Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins? | Cardiovascular Insights","twitter:description":"PCSK9 inhibitors are a new class of drugs, not yet FDA-approved, that have been shown to dramatically lower LDL cholesterol levels. Three clinicians discuss their potential. Video includes comments by Dylan Steen, MD, Department of Internal Medicine, Division of Cardiovascular Health and Disease, and UC Health cardiologist. View the video."},"aioseo_meta_data":{"post_id":"406","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"Article","isEnabled":true},"graphs":[]},"schema_type":null,"schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2021-02-26 09:37:07","updated":"2025-09-24 22:00:33","seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.uchealth.com\/cardiovascular-insights\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.uchealth.com\/cardiovascular-insights\/category\/articles\/\" title=\"Articles\">Articles<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tAre PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins?\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.uchealth.com\/cardiovascular-insights"},{"label":"Articles","link":"https:\/\/www.uchealth.com\/cardiovascular-insights\/category\/articles\/"},{"label":"Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins?","link":"https:\/\/www.uchealth.com\/cardiovascular-insights\/are-pcsk9-inhibitors-potentially-appropriate-for-patients-with-mixed-hyperlipidemia-and-high-cardiovascular-risk-despite-statins\/"}],"acf":[],"_links":{"self":[{"href":"https:\/\/www.uchealth.com\/cardiovascular-insights\/wp-json\/wp\/v2\/posts\/406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.uchealth.com\/cardiovascular-insights\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.uchealth.com\/cardiovascular-insights\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.uchealth.com\/cardiovascular-insights\/wp-json\/wp\/v2\/users\/85"}],"replies":[{"embeddable":true,"href":"https:\/\/www.uchealth.com\/cardiovascular-insights\/wp-json\/wp\/v2\/comments?post=406"}],"version-history":[{"count":3,"href":"https:\/\/www.uchealth.com\/cardiovascular-insights\/wp-json\/wp\/v2\/posts\/406\/revisions"}],"predecessor-version":[{"id":420,"href":"https:\/\/www.uchealth.com\/cardiovascular-insights\/wp-json\/wp\/v2\/posts\/406\/revisions\/420"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.uchealth.com\/cardiovascular-insights\/wp-json\/wp\/v2\/media\/418"}],"wp:attachment":[{"href":"https:\/\/www.uchealth.com\/cardiovascular-insights\/wp-json\/wp\/v2\/media?parent=406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.uchealth.com\/cardiovascular-insights\/wp-json\/wp\/v2\/categories?post=406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.uchealth.com\/cardiovascular-insights\/wp-json\/wp\/v2\/tags?post=406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}